New Oral Anticoagulants (NOAC) Study: Investigation of laboratory tests an development of a gold standard test for monitoring dabigatran and rivaroxaban therapy

New Oral Anticoagulants (NOAC) Study: Investigation of laboratory tests an development of a gold standard test for monitoring dabigatran and rivaroxaban therapy - NOAC study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON39575

Enrollment

120

Registered

2012-12-27

Start date

2012-11-01

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

blood clot thrombosis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients using dabigatran (CZE hospital) or rivaroxaban (MMC hospital) in a profylactic dose

Exclusion criteria

Exclusion criteria: renal failure (GFR

Design outcomes

Primary

Measure	Time frame
Several clotting tests are compared with each other and the gold standard to select the best test.	—

Secondary

Measure	Time frame
To determine target values for dabigatran concentrations with different dosage regimes	—

Countries

Netherlands

Outcome results